Bone Loss from Diabetes Drug Claimed In Invokana Lawsuit

April 19, 2016 – – TheProductLawyers.com announces a recent warning issued by the U.S. Food and Drug Administration (the FDA) regarding the type-2 diabetes drugs Invokamet and Invokana. These drugs may cause decreased bone density in those people taking the medications, which could increase their risk of developing bone fractures. The risk of bone fractures has been documented previously in the information that comes with the drugs. However, the FDA recently added new warnings to note further details, including that bone fractures were more common in patients taking Invokana than those taking a placebo.

The FDA has noted that as early as 12 weeks after treatment began, patients suffered bone fractures (usually of the upper extremities) and were of the low trauma variety. This means they occurred from falls that were of standing height or less. The commentary provided by the FDA indicates a link between fractures occurring easily and the drug in question.

Also discussed by the FDA is the observance of decreased bone mineral density. A study that evaluated 714 elderly patients showed that patients who took Invokana showed an increase in bone loss in the spine and hip areas. Higher doses of Invokana were also shown to be linked to additional bone loss.

Several years of FDA research has been devoted to the link between bone loss and Invokana as well as other SGLT2-inhibitors. Additionally, the Endocrinologic and Metabolic Drugs Advisory Committee issued a warning about bone fractures noted after 2013 clinical trials. There have been other warnings issued by the FDA regarding Invokana including links to the development of kidney failure, diabetic ketoacidosis, and urinary tract infections.

TheProductLawyers.com can provide you with additional information about Invokana and other SGLT2-inhibitor drugs as it becomes available. Anyone who has suffered from the adverse effects that they attribute to the use of these drugs is being offered complimentary legal consultations. Affected parties may be entitled to financial compensation.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009400